Sarclisa Combo Enhances Survival without Disease Progression in Newly Diagnosed Multiple Myeloma Patients Unfit for Transplant.
Significant Breakthrough in Multiple Myeloma Treatment: Sarclisa Combination Enhances Outcomes A recent study has shown promising results for patients diagnosed with newly diagnosed transplant-ineligible multiple myeloma, a challenging form of blood cancer that affects plasma cells in the bone marrow. The combination therapy involving Sarclisa (isatuximab), when used alongside standard treatments, has demonstrated a notable […]
Innate Pharma Reveals Positive Phase 2 Lacutamab Results for Mycosis Fungoides
Innate Pharma SA has reported positive outcomes from the Phase 2 TELLOMAK trial evaluating lacutamab for the treatment of mycosis fungoides, a type of cutaneous T-cell lymphoma. The study demonstrated that lacutamab, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, achieved promising efficacy and safety results in this patient population. The TELLOMAK trial, an open-label, multi-cohort study, assessed […]